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Abstract
To circumvent the limited availability of RNA extraction reagents, we aimed to develop a pro-
tocol for direct RT-qPCR to detect SARS-CoV-2 in nasopharyngeal swabs without RNA
extraction. Nasopharyngeal specimens positive for SARS-CoV-2 and other coronaviruses
collected in universal viral transport (UVT) medium were pre-processed by several commer-
cial and laboratory-developed methods and tested by RT-qPCR assays without RNA extrac-
tion using different RT-qPCR master mixes. The results were compared to that of standard
approach that involves RNA extraction. Incubation of specimens at 65˚C for 10 minutes
along with the use of TaqPath™ 1-Step RT-qPCR Master Mix provides higher analytical
sensitivity for detection of SARS-CoV-2 RNA than many other conditions tested. The opti-
mized direct RT-qPCR approach demonstrated a limit of detection of 6.6x103 copy/ml and
high reproducibility (co-efficient of variation = 1.2%). In 132 nasopharyngeal specimens sub-
mitted for SARS-CoV-2 testing, the sensitivity, specificity and accuracy of our optimized
approach were 95%, 99% and 98.5%, respectively, with reference to the standard
approach. Also, the RT-qPCR CT values obtained by the two methods were positively
correlated (Pearson correlation coefficient r = 0.6971, p = 0.0013). The rate of PCR inhibi-
tion by the direct approach was 8% compared to 9% by the standard approach. Our simple
approach to detect SARS-CoV-2 RNA by direct RT-qPCR may help laboratories continue
testing for the virus despite reagent shortages or expand their testing capacity in resource
limited settings.
Introduction
The ongoing pandemic of coronavirus disease (COVID-19) caused by a novel coronavirus,
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) posed an unprecedented pub-
lic health threat to the entire world. In the absence of an effective vaccine or specific treatment
against the virus, early detection and contact tracing, physical distancing measures and
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quarantine of cases are considered the cornerstones to curb the community transmission of
SARS-CoV-2 [1–3]. Since the virus was identified and its genome sequenced in early January
2020, detection of viral RNA in respiratory specimens by real-time reverse transcription PCR
(RT-qPCR) remains the main approach to manage the outbreak by allowing early detection of
cases and targeted measures to prevent transmission of the virus [4]. The massive demand for
SARS-CoV-2 RT-qPCR has brought about a global shortage and supply chain irregularities of
RNA extraction kits that are crucial for RT-qPCR testing [5–7]. Detection of viral pathogens
directly from clinical specimens without RNA extraction has been described earlier in cases
such as detection of norovirus from fecal specimens [8], human papilloma virus from crude
cell extracts [9], and Zika virus from blood or serum samples [10]. In this study, we tested a
number of commercial and laboratory-developed, specimen pre-treatment procedures to opti-
mize the performance of direct RT-qPCR for SARS-CoV-2 avoiding the RNA extraction step.
This method was validated against a standard approach that included extraction of viral RNA
on a commercial automated extraction platform.
Materials and methods
Standard approach for detection of SARS-CoV-2 RNA from nasopharyngeal specimens in our
laboratory involves extraction of total nucleic acids from specimens in an IVD-labeled, auto-
mated extraction platform followed by RT-qPCR, based on one of the assays (Table 1) sug-
gested by World Health Organization (WHO) [11]. The performance standards of the assay
were established in our laboratory according to College of American Pathologists (CAP) stan-
dards, and at time of writing this paper, the assay was used to test more than 2000 respiratory
specimens to screen patients for potential infection with SARS-CoV-2. Therefore, the assay
was used as the reference method for all other alternative approaches assessed in this study. All
specimen preparations, pre-treatments and PCR setup were performed in a Class II Biosafety
cabinet in a Biosafety level 2 (BSL2) facility.
Clinical specimens: Nasopharyngeal flocked swab (NPFS) specimens collected in universal
viral transport (UVT) medium (Becton, Dickinson and Company) (n = 180) submitted for
testing SARS-CoV-2 or other respiratory viruses at Sidra Medicine, Doha, Qatar were used in
this study. To maintain patient anonymity, each sample was coded, and all patient identifiers
were removed to ensure that personnel involved in this study were unaware of any patient
information. Ethics approval was not sought because the study involves laboratory validation
of test methods and the secondary use of anonymous pathological specimens that falls under
the category ‘exempted’ by Sidra Medicine Institutional Review Board. For spiking experi-
ments, NPFS specimens (n = 6) were collected from laboratory volunteers after obtaining
Table 1. Direct RT-qPCR on SARS-CoV-2 positive and negative NPFS specimens after heating at 65˚C for 10 minutes with different RT-qPCR master mixes.
Sample No. SARS-CoV-2 CT
Standard method Quantifast Pathogen RT-PCR + IC Master Mix PrimeDirect™ Probe RT-qPCR Mix TaqPath™ 1-Step RT-qPCR Master Mix
1 21.5 29.4 24.6 22.8
2 34.5 Undetermined Undetermined 35.3
3 24.5 30.4 28.7 25.5
4 22 29.9 31.4 25.8
5 Undetermined Undetermined Undetermined Undetermined
NPFS specimens were either subjected to viral RNA extraction by standard method using the NucliSENS easyMAG automated extraction system (bioMerieux), or
diluted 4-fold with NFW followed by incubation at 65˚C for 5 minutes. All samples were tested for SARS-CoV-2 RNA by standard RT-qPCR using different master
mixes in duplicate and mean CT values were compared.
https://doi.org/10.1371/journal.pone.0236564.t001
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written informed consents. No personal data were collected, and specimens were labeled with
random numbers so that test results cannot be linked to an individual.
Nucleic acid extraction: Nucleic acids from 0.2 ml of NPFS specimens were extracted on a
NucliSENS1 easyMAG platform (bioMe´rieux, France) according to the methods described by
the manufacturers.
Pre-treatment of specimens: Unless otherwise stated, specimens were diluted using nucle-
ase free water. Heat treatment of specimens at different temperature was performed in a Ther-
moMixer (Eppendorf). Specimens processed with Arcis Coronavirus RNA extraction research
kit (Arcis Biotechnology) were performed according to manufacturer’s instructions. Briefly,
90 μl specimen was mixed with 6 μl Reagent 1 RTU and either left unheated or heat lysed at
60˚C for 5 minutes. 40 μl of lysate was then mixed with 2 μl of Reagent 2a and was used directly
for Rt-qPCR. For Takara PrimeDirect™ Probe RT-qPCR Mix (Takara Bio), 0.2 ml specimens
were heated at 99˚C for 10 mins and then centrifuged at 4000rpm for 5 min. The supernatants
were collected and 7μl of supernatant was directly used in RT-qPCR reaction mixture.
RT-qPCR: Primers and probes for detection of SARS-CoV-2, HCoV-HKU1, RNaseP and
MS2 bacteriophage are listed in S1 Table [4,12–14]. For detection of HCoV-HKU1 using
Quantifast Pathogen RT-PCR + IC kit (Qiagen), five μl of extracted or pre-treated samples
were mixed with 20 μl of a master mix containing 5 μl of Quantifast Pathogen RT-PCR + IC
Master Mix, 0.25 μl of Quantifast RT Mix and 0.5 μl of 50 x ROX dye solution and primers
and probes to final concentrations shown in S1 Table. Thermal cycling was performed in a
ABI7500 Fast instrument (Thermofisher Scientific) with 1 cycle of reverse transcription at
50˚C for 20 min followed by 1 cycle of PCR activation at 95˚C for 5 min, followed by 40
amplification cycles each consisting of 95˚C-15s and 60˚C-60s. For detection of HCoV-
HKU1 using TaqPath™ 1-Step RT-qPCR kit (Thermofisher Scientific), five μl of extracted or
pre-treated samples were mixed with 5 μl of a master mix containing 5 μl of TaqPath™ 1-Step
RT-qPCR Master Mix and primers and probes to final concentrations shown in S1 Table.
Thermal cycling was performed in a ABI7500 Fast instrument (Thermofisher Scientific) with
1 cycle of reverse transcription at 50˚C for 15 min followed by 1 cycle of polymerase activa-
tion at 95˚C for 2 min, followed by 40 amplification cycles each consisting of 95˚C-15s and
60˚C-60s.
For detection of SARS-CoV-2 with standard method, five μl of nucleic acid extracts from
NucliSENS1 easyMAG system were mixed with 7.5 μl of a master mix containing 2.5 μl of
Quantifast Pathogen RT-PCR + IC Master Mix, 0.125 μl of Quantifast RT Mix and 0.25 μl of
50 X ROX dye solution and primers and probes to final concentrations shown in S1 Table.
RNA extraction and PCR inhibition were monitored by an internal control PCR assay or an
RNaseP assay, using the primers and probes shown in S1 Table. Specimens were spiked with a
tittered preparation of MS2 bacteriophage to serve as a template for internal control assay. For
direct PCR on specimens, pre-treated specimens were assessed in the same way except that
extracted MS2 bacteriophage RNA was mixed with PCR master mix to serve as an inhibition
control. A synthetic RNA (IDT) based on E-Sarbeco assay [4] amplicon sequence was used as
a positive control. As negative control, 0.2 ml neonatal calf serum (NCS) (Thermofisher Scien-
tific) was extracted along with specimens and used with each PCR run. SARS-CoV-2 RT-
qPCR with Takara PrimeDirect™ Probe RT-qPCR Mix was performed as described by the
manufacturer. Briefly, 7 μl of processed samples were mixed with 18 μl of master mix contain-
ing 12.5 μl of PrimeDirect Probe RT-qPCR Mix and primers and probes to final concentra-
tions shown in Table 1. Thermal cycling was performed in a ABI7500 Fast instrument
(Thermofisher Scientific) with 1 cycle of denaturation at 96˚C for 10 sec, 1 cycle of reverse
transcription at 60˚C for 5 min followed by 45 amplification cycles each consisting of 95˚C-5s
and 60˚C-30s. SARS-CoV-2 RT-qPCR with TaqPath™ 1-Step RT-qPCR kit with the optimized
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approach (specimens heat treated at 65˚C for 10 min) was performed as above except that 8 μl
of specimen was used per 20 μl reaction.
A total of 132 NPS that were previously tested by the standard approach were also tested
by the optimized, direct approach and the results were compared. An additional 30 NPS was
tested in the same way except that RNaseP was detected as an internal control or specimen
control instead of MS2 bacteriophage. In addition, an external quality assessment (EQA) panel
(8 specimens) from Quality Control for Molecular Diagnostics (QCMD) was tested simulta-
neously with the standard and the direct approach, as well as with a QIAstat-Dx Respiratory
2019-nCoV Panel (Qiagen) and the results were compared with expected results.
Limit of detection (LOD) study: A SARS-CoV-2 positive nasopharyngeal specimen (CT =
23.3) was titered by the optimized approach using synthetic RNA, and serially diluted (up to
5x10-7—fold) using a negative specimen. All diluted specimens were pre-treated by heating at
65˚C for 10 min and then assessed by SARS-CoV-2 RT-qPCR in replicates of 8. The CT values
obtained were used to calculate limit of detection (LOD) and intra-assay reproducibility of
direct RT-qPCR.
Statistical analysis: Sensitivity, defined as the number of true positive results divided by the
sum of true positive and false negative results; specificity, defined as the number of true nega-
tive results divided by the sum of true negative and false positive results; and accuracy (concor-
dance), defined as the sum of true positive and true negative results divided by the total
number of test samples, were calculated and expressed as percentages. Ninety-five percent
confidence intervals (CI) for sensitivity, specificity and accuracy were calculated by the Clop-
per-Pearson interval or exact method using an online, diagnostic test evaluation calculator
(MedCalc, 2018). Correlation between the RT-qPCR CT values between standard approach
and optimized direct approach was determined by Pearson’s coefficient calculator. The limit
of detection with 95% endpoint (C95) was determined by Probit regression analysis [15].
Results
Using a human coronavirus HKU1 (hCoV-HKU1) positive specimen as a surrogate for
SARS-CoV-2, we first assessed whether specimens can be used directly for RT-qPCR after
2–10 fold dilution with nuclease free water (NFW), simple heat treatment (100˚C for 5 min)
and centrifugation to remove any insoluble material that may be present in the specimen. The
pre-treated specimens were then assessed in parallel with extracted specimens by a previously
described, laboratory developed RT-qPCR for HCoV-HKU1 (S1 Table). A significant loss of
sensitivity was observed with a RT-qPCR ΔCT ranging from 10–14 (S2 Table). To determine
whether any components of UVT medium (Becton, Dickinson and Company) were inhibitory
to RT-qPCR, we collected nasopharyngeal flocked swabs (NPFS) from laboratory volunteers
in NFW along with swabs in UTM. We then spiked a SARS-CoV-2 positive specimen to all
specimens and assessed them by SARS-CoV-2 RT-qPCR. However, no significant improve-
ment in sensitivity was observed (S3 Table).
Similar results were observed when two commercial test kits were used for direct RT-
qPCR: Arcis Coronavirus RNA extraction research kit comes with lysis reagents that can be
used directly in RT-qPCR; and Takara PrimeDirect™ Probe RT-qPCR kit provides a master
mix that is compatible with heat-treated specimen extracts. However, in our evaluation
both test kits failed to demonstrate an acceptable level of sensitivity (S4 and S5 Tables). Our
attempts to further optimize the pre-treatment conditions showed modest improvement with
a non-ionic detergent, Tween-20, and further improvement with a heating step at 65˚C for
10 min without centrifugation (ΔCT = 5.2) (S6 Table). We then tested this low heat approach
with more SARS-CoV-2 positive specimens and using 3 different RT-qPCR master mixes.
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Interestingly, we found that with TaqPath™ 1-Step RT-qPCR Master Mix, 4/4 positive samples
were correctly detected with a ΔCT range 0.8–3.8 (Table 1). On the other hand, two other mas-
ter mixes gave higher ΔCT and 1/4 positive results were missed by both. Based on these results,
the optimal pre-treatment and reaction conditions for the direct approach were: i) transfer
and dilute (4-fold) 10 μl of NPFS specimen in NFW; ii) incubate at 65˚C for 10 min; and iii)
test 8 μl of heat lysed specimen in a 20 μl reaction using TaqPath™ 1-Step RT-qPCR Master
Mix.
The analytical sensitivity of the direct RT-qPCR assay using specimens prepared in this
manner was determined by serially diluting a specimen positive for SARS-CoV-2 with a nega-
tive specimen as a diluent. The positive specimen was titered based on the CT value obtained
by the direct approach using a standard curve prepared with SARS-CoV-2 synthetic RNA. The
CT values were linear (R
2 =>0.99) over the range of 103 copy/ml to 108 copy/ml, the highest
concentration used in this analysis (Fig 1A and 1B). The 95% limit of detection (LOD; C95) of
the assay with the direct approach was 6.6X103 copy/ml. The CT variation between RT-qPCR
replicates across different concentration of analytes were<1 with an average coefficient of var-
iation (CV%) of 1.2%.
A total of 132 NPFS specimens that were previously tested with standard approach includ-
ing viral RNA extraction were re-tested with the new direct approach. The direct approach
detected all except one positive case with CT>38. On the other hand, the direct approach
detected (CT>37) SARS-CoV-2 in one specimen that was negative by standard approach.
Overall agreement of results between two approaches was >98% (Kappa = 0.939; 95%
CI = 0.854 to 1.000). The sensitivity and specificity of the new approach compared to the refer-
ence method were 95% and 99%, respectively (Table 2). The RT-qPCR CT values for all speci-
mens that were positive by both methods (n = 18) were positively correlated with a Pearson
coefficient (R) of 0.6971 (p<0.01) (Fig 2). The rate of PCR inhibition among the specimens
that gave negative RT-qPCR results by the direct approach was 8% compared to 9% by the
standard approach. The direct approach accurately detected SARS-CoV-2 RNA in all except
one specimen in an external quality assessment (EQA) panel provided by Quality Control for
Molecular Diagnostics (QCMD) (S7 Table). The specimen that gave discrepant result was
reported as ‘borderline’ by QCMD, and SARS-CoV-2 RNA was also undetectable in this
Fig 1. Linearity of SARS-CoV-2 RT-qPCR by direct approach. A tittered SARS-CoV-2 positive nasopharyngeal specimen was
serially diluted using a negative specimen, pre-heated at 65˚C for 10 min and assessed by SARS-CoV-2 RT-qPCR as described in
the Supplemental methods. A) Amplification curves from SARS-CoV-2 RT-qPCR assay on the serially diluted sample. B) RT-
qPCR CT values were plotted against estimated copy number of SARS-CoV-2 RNA in each dilution. Each data point represents
an average of data obtained from 8 replicates.
https://doi.org/10.1371/journal.pone.0236564.g001
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specimen by standard approach and by a commercial test, QIAstat-Dx Respiratory 2019-
nCoV Panel (Qiagen).
Finally, we also tested our direct RT-qPCR approach using RNaseP as an internal control
or a specimen quality control within a duplex RT-qPCR with SARS-CoV-2 and compared the
results with that of the standard method involving RNA extraction (S8 Table). In 30 NPFS
specimens, RNaseP was detected in all specimens, but with an average loss of CT (ΔCT) by 4.2
±1.7 as compared to an average loss of SARS-CoV-2 CT by 2±1.3. Surprisingly, RNaseP was
not detected in two samples by the standard method that were positive for RNaseP by the
direct method. This could potentially be due to interfering substances concentrated by the
Table 2. Performance of optimized direct RT-qPCR approach with reference to standard approach for detection
of SARS-CoV-2 RNA.
Statistic Value 95% CI
Total number of specimens 132 -
True positive 18 -
True negative 112 -
False positive 1 -
False negative 1 -
Sensitivity 95.0% 74% to 99.8%
Specificity 99.0% 95.2% to 99.9%
Accuracy 98.5% 94.6% to 99.8%
https://doi.org/10.1371/journal.pone.0236564.t002
Fig 2. Correlation of RT = qPCR CT values obtained by direct versus standard approach.
https://doi.org/10.1371/journal.pone.0236564.g002
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extraction process. In this set, one sample that was positive for SARS-CoV-2 by standard
method with high CT (36.3) was missed by the direct method.
Discussion
Success in RT-qPCR testing depends on multiple factors. RNA extraction is preferable to the
use of direct specimens because the extraction process concentrates and purifies the RNA tar-
gets and excludes PCR inhibitory substances. The use of pre-treated or untreated specimens
directly in RT-qPCR is challenging because of the presence of inhibitors and RNA loss due
to heating and/or RNases. After many attempts with various pre-treatment agents and condi-
tions, we have determined an optimal pre-treatment protocol complemented with specific RT-
qPCR reagents, that generates results equivalent to standard methods that involve RNA extrac-
tion. Minimizing RNA loss through the low heat approach, appropriate dilution of inhibitory
substances and the higher sensitivity of TaqPath™ 1-Step RT-qPCR Master Mix may have
played a combinatory role in achieving equivalency of the direct RT-qPCR compared to a stan-
dard approach requiring viral RNA extraction. By the direct approach, the greater loss of RNa-
seP CT compared to SARS-CoV-2 CT may be due to the fact that heating of specimens at 65˚C
is more efficient for lysing viruses than nasopharyngeal epithelial cells and that a significant
fraction of viruses remains extracellularly. Indeed, we have observed that SARS-CoV-2 is dis-
tributed approximately 50:50 between the supernatant and pellet after centrifugation of NPFS
specimens (data not shown).
In summary, our new approach demonstrated high sensitivity and specificity in the detec-
tion of SARS-CoV-2 RNA, and the rate of RT-qPCR inhibition was similar to that of a stan-
dard approach. By skipping the RNA extraction step, the new approach will also significantly
reduce the cost and improve the turn-around time of the assay. Delayed and inadequate labo-
ratory testing can significantly hamper efforts to control the pandemic. Our results will help
many labs all over the world who are struggling with a shortage of reagents to continue testing
for SARS-CoV-2. Also, because of a significant reduction in cost, the optimized direct
approach we described, will be useful to resource-limited countries to expand their capacity
for RT-qPCR testing.
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S1 Table. Primers and probes used in this study.
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SENS easyMAG automated extraction system (bioMerieux), or ii) diluted 4-fold with nuclease
free water (NFW) iii) diluted 4-fold with nuclease free water (NFW) followed by incubation at
65˚C for 5 minutes or iv) diluted 4-fold with Tween-20 to final concentration of 0.2% followed
by incubation at room temperature for 10 min. All samples were tested for SARS-CoV-2 RNA
by standard RT-qPCR using Quantifast Pathogen RT-PCR + IC Master Mix.
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